SPPI Spectrum Pharmaceuticals Inc.

9.5
+0.03  (+0%)
Previous Close 9.47
Open 9.49
Price To Book 4.57
Market Cap 1,073,246,293
Shares 112,973,294
Volume 1,500,500
Short Ratio
Av. Daily Volume 792,155
Stock charts supplied by TradingView

NewsSee all news

  1. Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 London Healthcare Conference on November 21st

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage

  2. Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update

    Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an

  3. Spectrum Pharmaceuticals Announces Third Quarter 2019 Financial Results Conference Call

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the third quarter 2019

  4. Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS®

    ROLONTIS BLA filing is based on two large pivotal randomized controlled studies that met all primary and secondary endpoints. ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an

  5. Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

    Calidi Biotherapeutics, Inc. ("Calidi"), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data from Cohort 1 due December 2019. Cohort 2 data due mid-2020.
Poziotinib
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
Phase 2 initiation announced March 30, 2017 with preliminary data released October 18, 2017 - ORR 73%.
Poziotinib
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
FUSILEV
Colorectal cancer
CRL received July 5, 2009.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. New Phase 3 trial initiation announced August 14, 2017.
QAPZOLA - Apaziquone
Bladder cancer
BLA filing announced October 24, 2019.
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Belinostat
Peripheral T-Cell Lymphoma cancer
Phase 2 data at ASH December 2018.
Leucovorin
Peripheral T-Cell Lymphoma cancer

Latest News

  1. Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 London Healthcare Conference on November 21st

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage

  2. Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update

    Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an

  3. Spectrum Pharmaceuticals Announces Third Quarter 2019 Financial Results Conference Call

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the third quarter 2019

  4. Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS®

    ROLONTIS BLA filing is based on two large pivotal randomized controlled studies that met all primary and secondary endpoints. ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an

  5. Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

    Calidi Biotherapeutics, Inc. ("Calidi"), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George

  6. Spectrum Pharmaceuticals Announces Publication of Positive Poziotinib Data in Cancer Cell

    Publication highlights pre-clinical and clinical activity of poziotinib in lung cancer patients with HER2 mutations and potential future applications using monotherapy and combinations in many different mutated

  7. Spectrum Pharmaceuticals to Present Corporate Update at the 2019 Cantor Global Healthcare Conference on October 2nd

    Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage

  8. Spectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung Cancer

    Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and

  9. Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage